EFFECTS OF CHRONIC BROMOCRIPTINE TREATMENT OF AN ESTRONE-INDUCED, PROLACTIN-SECRETING RAT PITUITARY-ADENOMA

Bromocriptine (BROM), a dopamine (DA) agonist, is commonly and successfully used for long-term treatment of human prolactinomas. The effects of chronic BROM administration to female 344 Fisher/Lis rats bearing an estrone-induced, prolactin (PRL)-secreting pituitary tumor recently characterized as a model for human prolactinoma were studied. The animals were injected twice daily with BROM (2.5 mg/kg) or with diluent. After 1 mo. of treatment, the animals were sacrificed, and plasma collected and stored at -20.degree. C for PRL prolactin radioimmunoassay. The pituitary tumors were removed and tumoral mammotrophs dispersed enzymatically for studies of DA receptor binding and PRL release in vitro. BROM treatment significantly reduced tumor weight, cell size, rough endoplasmic reticulum, Golgi complexes and plasma PRL levels. [3H]-Spiroperidol binding to tumoral mammotrophs was also evaluated. BROM induced a significant decrease in the number of DA binding sites without any changes in affinity. Apparently, chronic BROM treatment of an animal model of prolactinoma induces tumor involution, reduction of PRL release and probably synthesis and down regulation of dopaminergic binding sites.